Amarin to Present at the Jefferies 2018 London Healthcare Conference
November 08 2018 - 6:00AM
Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company
focused on the commercialization and development of therapeutics to
improve cardiovascular health, announced today that John F. Thero,
Amarin's president and chief executive officer, is scheduled to
present a general company update at the Jefferies 2018 London
Healthcare Conference on Thursday, November 15, 2018, at 3:20 p.m.
Greenwich Mean Time (GMT) / 10:20 a.m. Eastern Time (ET) in London,
UK.
A live audio webcast of the presentation will be
available at: http://www.amarincorp.com, and will be accessible at
the same link for 30 days.
About Amarin
Amarin Corporation plc. is a rapidly growing,
innovative pharmaceutical company focused on developing
therapeutics to improve cardiovascular health. Amarin’s product
development program leverages its extensive experience in lipid
science and the potential therapeutic benefits of polyunsaturated
fatty acids. Vascepa (icosapent ethyl) is Amarin's first
FDA-approved drug and is available by prescription in the United
States, Lebanon and the United Arab Emirates. Amarin’s
commercial partners are pursuing additional regulatory approvals
for Vascepa in Canada, China and the Middle East. For more
information about Amarin, visit www.amarincorp.com.
Availability of other Information about
Amarin
Investors and others should note that Amarin
communicates with its investors and the public using the company
website http://www.amarincorp.com/), the investor relations website
(http://investor.amarincorp.com/), including but not limited to
investor presentations and investor FAQs, Securities and Exchange
Commission filings, press releases, public conference calls and
webcasts. The information that Amarin posts on these channels
and websites could be deemed to be material information. As a
result, Amarin encourages investors, the media, and others
interested in Amarin to review the information that is posted on
these channels, including the investor relations website, on a
regular basis. This list of channels may be updated from time
to time on Amarin’s investor relations website and may include
social media channels. The contents of Amarin’s website or
these channels, or any other website that may be accessed from its
website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor Relations:Elisabeth SchwartzInvestor
Relations and Corporate CommunicationsAmarin Corporation
plcIn U.S.: +1 (908)
719-1315investor.relations@amarincorp.com
Lee M. Stern Trout Group In U.S.: +1 (646)
378-2992lstern@troutgroup.com Media Inquiries: Christy Maginn
Burson-Marsteller In U.S.: +1 (646) 280-5210
Christy.Maginn@bm.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024